Volume 19, Issue 2

Apr
09

Society has long enjoyed the benefits of medical advances. In numerous cases, the biotechnology and pharmaceutical (biopharmaceutical) industries build on knowledge accumulated over centuries by traditional communities. As in the case of aspirin and morphine, the use of this knowledge has reduced the time and cost it takes to develop new drugs. Despite the community’s

Apr
09

This Article reconsiders the drugs-for-the-developing world debate that has taken place in the shadow of free trade liberalization. For the last twenty years, this debate has centered on a supposedly zero-sum conflict between access to drugs for residents of the “third world” and incentives for pharmaceutical multinationals to invest in research and development. Underlying this

Categories